Safety and tolerability of GS-9256 in treatment-naive patients with chronic genotype 1 hepatitis C virus infection: A randomised, double-blind, dose-escalation study
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2017
At a glance
- Drugs GS 9256 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 05 Nov 2010 New trial record.